Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac oral solution - Assertio Therapeutics/Novartis

Drug Profile

Diclofenac oral solution - Assertio Therapeutics/Novartis

Alternative Names: Cambia; Catafast; Dialrapid; Potassium diclofenac for oral solution; PRO-513; Voltfast

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Applied Pharma Research
  • Developer Assertio Therapeutics; CSC Pharmaceuticals Bulgaria; Novartis
  • Class Antimigraines; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 29 Jul 2019 Phase-I/II clinical trials in Migraine (PO) before July 2019 (Assertio Therapeutics pipeline, July 2019)
  • 04 Apr 2019 Launched for Migraine in Russia (PO)
  • 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top